Clinical course and risk factors for development and progression of interstitial lung disease in primary Sjogren's syndrome

被引:12
作者
Lee, Kyung-Ann [1 ]
Nam, Bo Da [2 ]
Hwang, Jung Hwa [2 ]
Kim, Hyun-Sook [1 ]
机构
[1] Soonchunhyang Univ, Seoul Hosp, Div Rheumatol, Dept Internal Med, 59 Daesagwan-ro, Seoul 04401, South Korea
[2] Soonchunhyang Univ, Seoul Hosp, Sch Med, Dept Radiol, Seoul, South Korea
关键词
D O I
10.1038/s41598-023-35608-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
This single-center, retrospective study aimed to investigate the course and prognostic factors of patients with primary Sjogren syndrome-associated interstitial lung disease (pSS-ILD). We included 120 pSS patients who underwent at least two high-resolution computed tomography (HRCT) scans between 2013 and 2021. Clinical symptoms, laboratory data, HRCT findings, and pulmonary function test results were collected. Two thoracic radiologists reviewed the HRCT findings. In patients with pSS without ILD at baseline (n = 81), no development of ILD was found on follow-up (median, 2.8 years). In patients with pSS-ILD (n = 39), total disease extent, extent of coarse reticulation, and traction bronchiectasis increased on HRCT, whereas the extent of ground glass opacity (GGO) decreased at follow-up (median, 3.2 years) (each p < 0.001). In progressive group of pSS-ILD (48.7%), the extent of coarse reticulation and coarseness score of fibrosis were increased at follow-up (p < 0.05). Usual interstitial pneumonia pattern on CT (OR, 15.237) and follow-up duration (OR, 1.403) were independent risk factors for disease progression in patients with pSS-ILD. In both progressive and non-progressive pSS-ILD, GGO decreased, whereas the extent of fibrosis increased even after treatment with glucocorticoid and/or immunosuppressants. In conclusion, progression occurred in approximately half of the pSS-ILD patients with slow gradual deterioration. Our study identified a definite group of progressive pSS-ILD who did not respond to current anti-inflammatory treatment.
引用
收藏
页数:12
相关论文
共 24 条
[1]   Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjogren syndrome [J].
Buvry, Charlotte ;
Cassagnes, Lucie ;
Tekath, Marielle ;
Artigues, Maxime ;
Pereira, Bruno ;
Rieu, Virginie ;
Le Guenno, Guillaume ;
Tournadre, Anne ;
Ruivard, Marc ;
Grobost, Vincent .
RESPIRATORY MEDICINE, 2020, 163
[2]   Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality [J].
Edey, Anthony J. ;
Devaraj, Anand A. ;
Barker, Robert P. ;
Nicholson, Andrew G. ;
Wells, Athol U. ;
Hansell, David M. .
EUROPEAN RADIOLOGY, 2011, 21 (08) :1586-1593
[3]   Interstitial lung disease in systemic sclerosis - A simple staging system [J].
Goh, Nicole S. L. ;
Desai, Sujai R. ;
Veeraraghavan, Srihari ;
Hansell, David M. ;
Copley, Susan J. ;
Maher, Toby M. ;
Corte, Tarnera J. ;
Sander, Clare R. ;
Ratoff, Jonathan ;
Devaraj, Anand ;
Bozovic, Gracijela ;
Denton, Christopher P. ;
Black, Carol M. ;
du Bois, Roland M. ;
Wells, Athol U. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (11) :1248-1254
[4]   Clinical profiles of SS-ILD compared with SS-NILD in a Chinese population: a retrospective analysis of 735 patients [J].
Guo, Ting ;
Long, Yaomei ;
Shen, Qinxue ;
Guo, Wei ;
Duan, Wang ;
Ouyang, Xiaoli ;
Peng, Hong .
ANNALS OF MEDICINE, 2021, 53 (01) :1340-1348
[5]   Fleischner Society:: Glossary of terms tor thoracic imaging [J].
Hansell, David M. ;
Bankier, Alexander A. ;
MacMahon, Heber ;
McLoud, Theresa C. ;
Mueller, Nestor L. ;
Remy, Jacques .
RADIOLOGY, 2008, 246 (03) :697-722
[6]   Risk factors for progression of interstitial lung disease in Sjogren's syndrome: a single-centered, retrospective study [J].
He, Shi-Hao ;
He, Yu-Jie ;
Guo, Kuang-Jin ;
Liang, Xu ;
Li, Shan-Shan ;
Li, Tian-Fang .
CLINICAL RHEUMATOLOGY, 2022, 41 (04) :1153-1161
[7]   Video clip assessment of a salivary gland ultrasound scoring system in Sjogren's syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise [J].
Jousse-Joulin, Sandrine ;
D'Agostino, Maria Antonietta ;
Nicolas, Celine ;
Naredo, Esperanza ;
Ohrndorf, Sarah ;
Backhaus, Marina ;
Tamborrini, Giorgio ;
Chary-Valckenaere, Isabelle ;
Terslev, Lene ;
Iagnocco, Annamaria ;
Collado, Paz ;
Hernandez-Diaz, Cristina ;
Gandjbakhch, Frederique ;
Schmidt, Wolfgang A. ;
Filippou, Georgios ;
Dejaco, Christian ;
Stradner, Martin Helmut ;
Mortada, Mohamed Atia ;
Hocevar, Alojzija ;
Chrysidis, Stavros ;
El Mardenly, Ghada ;
Jose de Agustin, Juan ;
Thiele, Ralf ;
MacCarter, Daryl K. ;
Finzel, Stephanie ;
Hanova, Petra ;
Zabotti, Alen ;
Glaser, Cornelia ;
Alavi, Zarrin ;
Hammenfors, Daniel Sten ;
Gatineau, Florence ;
Bruyn, George A. W. .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (07) :967-973
[8]   Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice [J].
Khanna, Dinesh ;
Lescoat, Alain ;
Roofeh, David ;
Bernstein, Elana J. ;
Kazerooni, Ella A. ;
Roth, Michael D. ;
Martinez, Fernando ;
Flaherty, Kevin R. ;
Denton, Christopher P. .
ARTHRITIS & RHEUMATOLOGY, 2022, 74 (01) :13-27
[9]   Long-term clinical course and outcome in patients with primary Sjogren syndrome-associated interstitial lung disease [J].
Kim, Yun Jae ;
Choe, Jooae ;
Kim, Ho Jeong ;
Song, Jin Woo .
SCIENTIFIC REPORTS, 2021, 11 (01)
[10]   Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjogren's [J].
Lee, Augustine S. ;
Scofield, R. Hal ;
Hammitt, Katherine Morland ;
Gupta, Nishant ;
Thomas, Donald E. ;
Moua, Teng ;
Ussavarungsi, Kamonpun ;
St Clair, E. William ;
Meehan, Richard ;
Dunleavy, Kieron ;
Makara, Matt ;
Carsons, Steven E. ;
Carteron, Nancy L. .
CHEST, 2021, 159 (02) :683-698